Biosynex Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Larry Abensur

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	9.4yrs
Proprietà del CEO	6.2%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	9.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Larry Abensur

9.4yrs

Mandato

Mr. Larry Abensur has served as a Director at Biosynex S.A. since June 24, 2015 and serves as the Chief Executive Officer at Biosynex SA. He serves as the Chairman of Biosynex S.A. Mr. Abensur serves as th...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Larry Abensur	Chairman & CEO	9.4yrs	Nessun dato	6.2% € 1.9m
Thierry Paper	Deputy CEO & Director	9.4yrs	€127.30k	0.99% € 299.7k
Thomas Lamy	Deputy CEO & Director	9.4yrs	Nessun dato	1.56% € 470.9k
Felix Agbalika	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Emmanuel Drouet	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Denis Gallot	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Vincent Sapin	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Marc Noizet	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Elie Fraenckel	Director	no data	Nessun dato	Nessun dato

9.4yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0DL sono considerati esperti (durata media dell'incarico 9.4 anni).

Biosynex Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Biosynex SA, Annual General Meeting, Jun 07, 2024

No independent directors

No independent directors

Recent updates

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

New minor risk - Shareholder dilution

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 24%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Full year 2020 earnings released: EPS €3.43 (vs €0.12 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media